HRP20230362T1 - Kompozicije koje sadrže triciklične heterorociklične spojeve - Google Patents
Kompozicije koje sadrže triciklične heterorociklične spojeve Download PDFInfo
- Publication number
- HRP20230362T1 HRP20230362T1 HRP20230362TT HRP20230362T HRP20230362T1 HR P20230362 T1 HRP20230362 T1 HR P20230362T1 HR P20230362T T HRP20230362T T HR P20230362TT HR P20230362 T HRP20230362 T HR P20230362T HR P20230362 T1 HRP20230362 T1 HR P20230362T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- mass
- alkyl
- composition according
- formula
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 31
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000314 lubricant Substances 0.000 claims 9
- 239000011230 binding agent Substances 0.000 claims 6
- 239000007884 disintegrant Substances 0.000 claims 6
- 239000000945 filler Substances 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 150000003890 succinate salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000008184 oral solid dosage form Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000012748 slip agent Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (18)
1. Farmaceutski sastav koji sadrži spoj formule I u obliku njegove sukcinantne soli, i najmanje jedno farmaceutsko pomoćno sredstvo koje je izabrano iz grupe koja čine punila, vezivna sredstva, dezintegranti, sredstva za klizanje i lubrikanti, pri čemu je spoj prema formuli I predstavljen:
[image]
pri čemu:
W je O, N-H, N-(C1-C10 alkil) ili S;
svaki X je nezavisno CH ili N;
R1 je 5 do 7-člani zasićen ili nezasićen, po potrebi zamijenjen heterocikl koji sadrži najmanje 1 heteroatom izabran između N ili O;
R2 je LY;
svaki L je direktna veza, C1-C10 alkilen, C2-C10 alkenilen ili C2-C10 alkinilen;
Y je po potrebi zamijenjen spojeni, premošćeni ili spirociklični nearomatični 5-12-člani heterocikl koji sadrži do 4 heteroatoma izabranih između N ili O; i
svaki R3 je nezavisno H, C1-C10 alkil, halogen, fluoro C1-C10 alkil, O-C1-C10 alkil, NH-C1-C10 alkil, S-C1-C10 alkil, O-fluoro C1-C10 alkil, NH-acil, NH-C(O)-NH-C1-C10 alkil, C(O)-NH-C1-C10 alkil, aril ili heteroaril.
2. Sastav prema zahtjevu 1, gdje je spoj prema formuli I prisutno u količini od 0.1 do 50 masenih % na osnovu ukupne mase sastava, poželjno 5 do 30 masenih % na osnovu ukupne mase sastava.
3. Kompozicija prema zahtjevima 1 ili 2, gdje je punilo sredstvo za punjenje prisutno u količini od 10 do 90 masenih % na osnovu ukupne mase sastava, i/ili gdje je vezivno sredstvo prisutno u količini od 0.1 do 20 masenih % na osnovu ukupne mase sastava, i/ili gdje je dezintegrant prisutan u količini sa od 1 do 20 masenih % na osnovu ukupne mase sastava, i/ili gdje je lubrikans prisutan u količini sa od 0.1 do 10 masenih %, poželjno od 0.5 do 5 masenih % na osnovu ukupne mase kompozicije.
4. Sastav prema bilo kojem od prethodnih zahtjeva, gdje sastav obuhvaća:
1 do 50 masenih % spojeva prema zahtjevu 1;
10 do 90 masenih % najmanje jednog punila ;
0.1 do 20 masenih % najmanje jednog vezivnog sredstva;
1 do 20 masenih % najmanje jednog dezintegranta; i
0.1 do 10 masenih % od najmanje jednog lubrikanta ili sredstva za klizanje.
5. Farmaceutski sastav koja sadrži spoj formule I ili njegovu farmaceutski prihvatljivu sol, i najmanje jedno farmaceutsko pomoćno sredstvo izabrano iz grupe koju čine punila, vezivna sredstva, dezintegranti, sredstva za klizanje i lubrikanti, pri čemu je spoj prema formuli I predstavljen:
[image]
pri čemu:
W je O, N-H, N-(C1-C10 alkil) ili S;
svaki X je nezavisno CH ili N;
R1 je 5 do 7-člani zasićen ili nezasićen, po potrebi zamijenjen heterocikl koji sadrži najmanje 1 heteroatom izabran između N ili O;
R2 je LY;
svaki L je direktna veza, C1-C10 alkilen, C2-C10 alkenilen ili C2-C10 alkinilen;
Y je po potrebi zamijenjen spojeni, premošćeni ili spirociklični nearomatični 5-12-člani heterocikl koji sadrži do 4 heteroatoma izabranih između N ili O; i
svaki R3 je nezavisno H, C1-C10 alkil, halogen, fluoro C1-C10 alkil, O-C1-C10 alkil, NH-C1-C10 alkil, S-C1-C10 alkil, O-fluoro C1-C10 alkil, NH-acil, NH-C(O)-NH-C1-C10 alkil, C(O)-NH-C1-C10 alkil, aril ili heteroaril;
sastav obuhvaća:
1 do 50 masenih % spojeva formule I ili njegove farmaceutski prihvatljive soli;
10 do 90 masenih % najmanje jednog punila;
0.1 do 20 masenih % najmanje jednog vezivnog sredstva;
1 do 20 masenih % najmanje jednog dezintegranta; i
0.1 do 10 masenih % najmanje jednog lubrikanta ili sredstva za klizanje.
6. Sastav prema zahtjevu 5, što je spoj prema formuli I u obliku svoje sukcinatne soli.
7. Sastav prema bilo kojem od prethodnih zahtjeva, koje dalje sadrži površinski aktivnu supstancu, poželjno u količini od 0.1 do 5 masenih % na osnovu ukupne mase sastava.
8. Sastav prema bilo kojem od prethodnih zahtjeva, gdje je kompozicija u obliku čvrstog doznog oblika, poželjno oralnog čvrstog doznog oblika, poželjno u obliku tablete ili kapsule.
9. Sastav prema bilo kojem od prethodnih zahtjeva, gdje kompozicija obuhvaća najmanje dva ili najmanje tri farmaceutska pomoćna sredstva.
10. Sastav prema bilo kojem od zahtjeva 5 do 9, gdje je lubrikant prisutan u količini od 0.5 do 5 masenih % na osnovu ukupne mase sastava.
11. Sastav prema bilo kojem od prethodnih zahtjeva, gdje je R1 predstavljen bilo kojom od sljedećih struktura :
[image]
poželjno gdje je R1 morfolin.
12. Sastav prema bilo kojem od prethodnih zahtjeva, pri čemu W je O ili S, poželjno gdje W je O i/ili gde X je CH, i/ili gde R3 jeH, i/ili gde L je C1-C10 alkilen, poželjno metilen.
13. Sastav prema bilo kojem od prethodnih zahtjeva, gdje Y sadrži jedan ili dva heteroatoma, poželjno dva heteroatoma.
14. Sastav prema bilo kojem od prethodnih zahtjeva, pri čemu je Y izabran između:
[image]
pri čemu:
A je izabrano između O, S, NR4 ili po potrebi zamijenjen C1-C3 alkilen, C2-C3 alkenilen, ili C2-C3 alkinilen;
B je NR4, O ili CH2;
pri čemu R4 je H ili po potrebi zamijenjen C1-C10 alkil, C2-C10 alkenil ili C2-C10 alkinil;
p može biti 0 ili 1;
svako m je nezavisno izabrano između 0, 1 ili 2; i
svako n je nezavisno izabrano između 1, 2 ili 3.
15. Sastav prema bilo kojem od prethodnih zahtjeva, gdje je spoj prema formuli I prikazano bilo kojom od sljedećih struktura:
[image]
[image]
[image]
[image]
16. Sastav prema bilo kojem od prethodnih zahtjeva, za upotrebu u terapiji.
17. Sastav za upotrebu prema zahtjevu 16, gdje je terapija rak, poželjno leukemija ili PTEN- negativan solidan tumor, imunološki poremećaj ili inflamatorni poremećaj, poželjno reumatoidni artritis.
18. Postupak za proizvodnju farmaceutskog sastava, prema bilo kojem od zahtjeva 1 do 15, koji obuhvaća:
a) miješanje spojeva prema formuli I sa najmanje jednim farmaceutskim pomoćnim sredstvom izabranim iz grupe koju čine punila, vezivna sredstva, dezintegranti, sredstva za klizanje i lubrikanti da bi se formirala smijesa;
b) prerada smijese u farmaceutski sastav; ili
c) komprimiranje sastava iz koraka (b) u tabletu,
po potrebi, pri čemu korak (b) dalje obuhvaća prosijavanje kako bi se osigurala veličina čestica manja od 1000 μm, poželjno manja od 500 μm.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1514758.0A GB201514758D0 (en) | 2015-08-19 | 2015-08-19 | Formulation |
| EP16756765.0A EP3337460B1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising tricyclic heterocyclic compounds |
| PCT/GB2016/052577 WO2017029518A1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising tricyclic heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230362T1 true HRP20230362T1 (hr) | 2023-06-09 |
Family
ID=54258857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230362TT HRP20230362T1 (hr) | 2015-08-19 | 2016-08-19 | Kompozicije koje sadrže triciklične heterorociklične spojeve |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20180235974A1 (hr) |
| EP (1) | EP3337460B1 (hr) |
| JP (1) | JP6986757B2 (hr) |
| KR (1) | KR20180066041A (hr) |
| CN (1) | CN108135855B (hr) |
| AU (1) | AU2016307886B9 (hr) |
| CA (1) | CA2995896A1 (hr) |
| DK (1) | DK3337460T3 (hr) |
| ES (1) | ES2941741T3 (hr) |
| GB (1) | GB201514758D0 (hr) |
| HK (1) | HK1251465A1 (hr) |
| HR (1) | HRP20230362T1 (hr) |
| IL (1) | IL257501B (hr) |
| LT (1) | LT3337460T (hr) |
| MX (1) | MX2018001925A (hr) |
| PT (1) | PT3337460T (hr) |
| SI (1) | SI3337460T1 (hr) |
| WO (1) | WO2017029518A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534326T3 (es) | 2009-08-20 | 2015-04-21 | Karus Therapeutics Limited | Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| BE786081A (fr) | 1971-07-13 | 1973-01-10 | Uniroyal Sa | Appareil et procede pour maintenir les tringles des bourrelets de pneu |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| UA72922C2 (uk) * | 1999-08-03 | 2005-05-16 | Ліллі Айкос Ллк | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| DE60144322D1 (de) | 2000-04-27 | 2011-05-12 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
| AU2001270260A1 (en) | 2000-06-30 | 2002-01-14 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| EP1755609A1 (en) | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| MX2007014619A (es) | 2005-05-20 | 2009-02-13 | Vertex Pharma | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. |
| CA2635899A1 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| BRPI0710866A2 (pt) | 2006-04-26 | 2012-08-14 | Hoffmann La Roche | compostos farmacÊuticos |
| EP2046799B1 (en) | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| ATE510840T1 (de) | 2006-06-26 | 2011-06-15 | Ucb Pharma Sa | Kondensierte thiazol-derivate als kinasehemmer |
| CA2669399A1 (en) | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| WO2008076447A2 (en) | 2006-12-15 | 2008-06-26 | Ordway Research Institute | Treatments of therapy-resistant diseases comprising drug combinations |
| WO2008094992A2 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| US20100063032A1 (en) | 2007-03-28 | 2010-03-11 | Debenham John S | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| US20110201608A1 (en) | 2008-08-05 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and use thereof as medicines |
| EP2344490A2 (en) | 2008-10-03 | 2011-07-20 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| ES2534326T3 (es) * | 2009-08-20 | 2015-04-21 | Karus Therapeutics Limited | Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa |
| US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| MY161925A (en) | 2011-07-27 | 2017-05-15 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| EP2922851B8 (en) | 2012-11-20 | 2017-09-27 | F. Hoffmann-La Roche AG | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| SI2994465T1 (sl) | 2013-05-10 | 2018-10-30 | Karus Therapeutics Limited | Novi inhibitorji histon deacetilaze |
| AU2014273946B2 (en) | 2013-05-30 | 2020-03-12 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| MA40933A (fr) * | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
-
2015
- 2015-08-19 GB GBGB1514758.0A patent/GB201514758D0/en not_active Ceased
-
2016
- 2016-08-19 CA CA2995896A patent/CA2995896A1/en not_active Abandoned
- 2016-08-19 LT LTEPPCT/GB2016/052577T patent/LT3337460T/lt unknown
- 2016-08-19 MX MX2018001925A patent/MX2018001925A/es unknown
- 2016-08-19 KR KR1020187007560A patent/KR20180066041A/ko unknown
- 2016-08-19 JP JP2018508752A patent/JP6986757B2/ja active Active
- 2016-08-19 PT PT167567650T patent/PT3337460T/pt unknown
- 2016-08-19 HR HRP20230362TT patent/HRP20230362T1/hr unknown
- 2016-08-19 US US15/753,359 patent/US20180235974A1/en not_active Abandoned
- 2016-08-19 CN CN201680057451.6A patent/CN108135855B/zh active Active
- 2016-08-19 SI SI201631671T patent/SI3337460T1/sl unknown
- 2016-08-19 DK DK16756765.0T patent/DK3337460T3/da active
- 2016-08-19 WO PCT/GB2016/052577 patent/WO2017029518A1/en active Application Filing
- 2016-08-19 ES ES16756765T patent/ES2941741T3/es active Active
- 2016-08-19 EP EP16756765.0A patent/EP3337460B1/en active Active
- 2016-08-19 AU AU2016307886A patent/AU2016307886B9/en not_active Ceased
-
2018
- 2018-02-13 IL IL257501A patent/IL257501B/en not_active IP Right Cessation
- 2018-08-24 HK HK18110945.5A patent/HK1251465A1/zh unknown
-
2020
- 2020-10-15 US US17/071,543 patent/US11779586B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108135855B (zh) | 2021-04-02 |
| CA2995896A1 (en) | 2017-02-23 |
| US20210275537A1 (en) | 2021-09-09 |
| US20180235974A1 (en) | 2018-08-23 |
| WO2017029518A1 (en) | 2017-02-23 |
| MX2018001925A (es) | 2018-06-19 |
| IL257501A (en) | 2018-04-30 |
| LT3337460T (lt) | 2023-03-27 |
| AU2016307886A1 (en) | 2018-03-08 |
| KR20180066041A (ko) | 2018-06-18 |
| SI3337460T1 (sl) | 2023-04-28 |
| EP3337460B1 (en) | 2023-02-15 |
| CN108135855A (zh) | 2018-06-08 |
| ES2941741T3 (es) | 2023-05-25 |
| JP6986757B2 (ja) | 2021-12-22 |
| PT3337460T (pt) | 2023-04-21 |
| GB201514758D0 (en) | 2015-09-30 |
| HK1251465A1 (zh) | 2019-02-01 |
| US11779586B2 (en) | 2023-10-10 |
| AU2016307886B2 (en) | 2019-07-18 |
| EP3337460A1 (en) | 2018-06-27 |
| DK3337460T3 (en) | 2023-04-11 |
| IL257501B (en) | 2020-03-31 |
| AU2016307886B9 (en) | 2019-11-21 |
| JP2018523688A (ja) | 2018-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230362T1 (hr) | Kompozicije koje sadrže triciklične heterorociklične spojeve | |
| HRP20180768T1 (hr) | Triciklički heterociklički spojevi kao inhibitori fosfoinositid-3-kinaze | |
| HRP20210377T1 (hr) | Il-2rbeta-selektivni agonisti u kombinaciji s anti-ctla-4 protutijelom ili anti-pd-1 protutijelom | |
| HRP20191901T1 (hr) | Ciklizirani derivati sulfamoilarilamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20170352T1 (hr) | Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori | |
| JOP20210241A1 (ar) | مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان | |
| PE20190662A1 (es) | Composiciones farmaceuticas que contienen derivados de piridona policiclicos sustituidos y profarmaco de los mismos | |
| PH12018501068A1 (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| HRP20210447T1 (hr) | Piridinski spoj | |
| HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
| HRP20171302T1 (hr) | Makrociklički derivati piridazinona | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| EA201592252A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
| SI2953948T1 (en) | FLUORINATED INTEGRIN ANTAGONISTS | |
| CY1122231T1 (el) | Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη | |
| EA201700504A1 (ru) | 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение | |
| EA201992679A1 (ru) | N-замещенные индольные производные | |
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| MA38854A1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| HRP20201932T1 (hr) | Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba | |
| HRP20201985T1 (hr) | Piridonski spoj kao c-met inhibitor | |
| HRP20220710T1 (hr) | Antiproliferacijski spojevi i njihova uporaba |